MET Form 4: Director Robert G. Hubbard receives 916 shares at $81.93

Rhea-AI Filing Summary

Robert Glenn Hubbard, a non-management director of MetLife, Inc. (MET), reported an acquisition of 916 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After this transaction, the filing shows 102,067 shares beneficially owned directly by the reporting person.

The filing notes these shares were issued as part of MetLife's non-management director compensation and that the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025.

Positive

• Director increased direct ownership to 102,067 shares, signaling alignment with shareholders
• Compensation paid in stock and election to defer under the Deferred Compensation Plan aligns director incentives with long-term performance

Negative

• None.

Insights

Corporate Governance Expert

Director purchased 916 shares and elected deferred compensation.

This Form 4 documents a routine director compensation stock issuance and deferral election rather than a market-driven open-market purchase. The transaction is recorded as an acquisition of 916 shares at $81.93 on 10/01/2025, raising direct holdings to 102,067 shares.

This is governance-relevant because compensation paid in stock and deferral elections link director pay to shareholder outcomes and can indicate alignment without implying discretionary insider trading.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

HUBBARD ROBERT GLENN

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A(1)		916	A	$81.93	102,067	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees and Board Chair retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did MetLife director Robert G. Hubbard report on Form 4 (MET)?

The Form 4 reports an acquisition of 916 shares on 10/01/2025 at a price of $81.93 per share.

How many MetLife (MET) shares does the reporting director own after this transaction?

The filing shows the director beneficially owns 102,067 shares following the reported transaction.

Was this a market purchase or compensation-related issuance?

The shares were issued as part of non-management director compensation and the director elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 signed and filed?

The signature by attorney-in-fact appears dated 10/03/2025 and the transaction date is 10/01/2025.

What price per share is reported on the Form 4?

The reported price is $81.93 per share for the 916 shares.